What are the considerations for testosterone replacement therapy (TRT) in a perimenopausal woman with low libido or decreased sexual function?

Testosterone Replacement Therapy in Perimenopause

Testosterone therapy is not routinely recommended for perimenopausal women with low libido, as current evidence supports its use primarily in postmenopausal women with hypoactive sexual desire disorder (HSDD) after bilateral oophorectomy or natural menopause—not during the perimenopausal transition. 1, 2

Key Evidence Limitations for Perimenopausal Use

The critical distinction here is timing: perimenopause represents an active hormonal transition with fluctuating estrogen and testosterone levels, whereas the evidence base for testosterone therapy specifically targets postmenopausal women with established ovarian senescence. 1, 2

• No guideline-level evidence supports testosterone use during perimenopause specifically—all major society recommendations (North American Menopause Society, ACOG) focus on postmenopausal populations. 2, 1
• Endogenous testosterone levels have not been clearly linked to sexual function even in postmenopausal women, making the rationale for supplementation during perimenopause even weaker. 2
• Clinically available laboratory assays do not accurately detect testosterone concentrations at values typically found in women, rendering diagnosis of "testosterone deficiency" unreliable. 2

When Testosterone May Be Considered (Postmenopausal Context)

If this patient progresses to confirmed postmenopause, testosterone therapy becomes a legitimate consideration under specific circumstances:

Eligibility Criteria

• Postmenopausal status confirmed (not perimenopausal). 2, 3
• Hypoactive sexual desire disorder causing personal distress. 2, 4
• No other identifiable causes ruled out (physical factors, psychosocial stressors, medications, relationship issues). 2
• Physiologic cause for reduced testosterone present (bilateral oophorectomy is the strongest indication). 2, 3

Evidence of Benefit

• Randomized controlled trials demonstrate transdermal testosterone patches improve sexual desire, arousal, and orgasmic response in postmenopausal women, particularly those with surgical menopause. 2, 3, 4
• Approximately 40% of postmenopausal women experience decreased sexual desire causing distress, and testosterone addresses this where estrogen therapy alone fails. 4

Formulation and Dosing Recommendations

No testosterone product is specifically formulated or approved for women in Europe or North America, creating significant practical challenges. 4, 5

Preferred Approach

• Transdermal preparations (patches, gels, creams) are strongly preferred over oral formulations due to avoidance of first-pass hepatic metabolism. 2, 4
• Suggested starting dose: 5 mg transdermal testosterone daily or less (gel or cream). 4
• Products formulated for men carry risk of excessive dosing and require careful dose adjustment. 2
• Custom-compounded products should be used with extreme caution due to inconsistent dosing. 2

Monitoring Requirements

• Monitor for supraphysiologic testosterone levels before and during therapy—not to diagnose deficiency, but to prevent overdosing. 2
• Target testosterone levels at the upper portion or slightly above the reference range for reproductive-aged women. 6
• Assess subjective sexual response, desire, and satisfaction at regular intervals. 2
• Evaluate for adverse effects including hirsutism, acne, and voice changes. 2, 6

Safety Profile and Contraindications

Absolute Contraindications

• Breast cancer or uterine cancer (hormone-sensitive malignancies). 2, 7
• Cardiovascular disease. 2
• Liver disease. 2
• Pregnancy or breastfeeding. 2

Short-Term Safety Data (Up to 2 Years)

• No increased risk of hepatotoxicity or endometrial hyperplasia at appropriate doses. 6, 7
• Mild and reversible acne and hirsutism are common. 6, 8
• Changes to lipid profile occur with oral (but not transdermal) testosterone. 6
• No adverse cardiovascular effects including blood pressure changes, arterial vascular reactivity, or polycythemia demonstrated. 6

Unknown Long-Term Risks

• Breast cancer risk remains unclear—some experimental data suggest testosterone may decrease estrogen-induced breast epithelial proliferation, but definitive evidence is lacking. 6, 2
• Long-term cardiovascular and thromboembolic risks are not established. 2
• Safety data beyond 6 months are limited. 2

Critical Clinical Pitfalls

• Do not prescribe testosterone during active perimenopause—wait until postmenopausal status is confirmed. 2, 1
• Do not use testosterone without concomitant estrogen therapy in postmenopausal women—evidence for testosterone-alone therapy is insufficient. 2, 1
• Do not prescribe testosterone for indications other than HSDD—data are inadequate for bone density, hot flashes, lean body mass, or general well-being. 2
• Do not use testosterone levels to diagnose "androgen deficiency"—no specific testosterone level correlates with clinical symptoms. 2
• Do not use oral testosterone preparations—transdermal routes avoid hepatic first-pass effects. 2, 4

Alternative Management During Perimenopause

For this perimenopausal patient with low libido:

• Address modifiable factors first: medications (oral contraceptives, SSRIs, antihypertensives), relationship issues, depression, anxiety, sleep disturbance, chronic illness. 2
• Consider estrogen-progestin hormone therapy if vasomotor symptoms are present—this addresses perimenopausal symptoms but will not improve libido. 1
• Refer for psychosexual counseling to address non-hormonal contributors to sexual dysfunction. 2
• Reassess after confirmed postmenopause if HSDD persists despite addressing other factors. 2, 4

Duration and Discontinuation

• Use the lowest effective dose for the shortest time that meets treatment goals. 2, 1
• Reassess necessity at regular intervals (at minimum annually). 1
• No specific maximum duration is established, but safety data beyond 2 years are lacking. 6, 2